Literature DB >> 3004729

Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial.

M J Ravry, G A Omura, A A Bartolucci, L Einhorn, B Kramer, E Davila.   

Abstract

Entities:  

Mesh：

Year:  1986        PMID： 3004729

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  2 in total

1.  Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells.

Authors:  A C Okaro; D A Fennell; M Corbo; B R Davidson; F E Cotter
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

2.  Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma.

Authors:  S K Ji; N H Park; H M Choi; Y W Kim; S H Lee; K H Lee; S Y Ahn; S U Lee; B H Han; B C Park
Journal:  Korean J Intern Med       Date:  1996-01       Impact factor: 2.884
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.